Trial Profile
A multicenter, randomized, double-blind, placebo-controlled, pivotal adaptive phase II/III/IV clinical trial of Remogliflozin Etabonate in patients with Nonalcoholic steatohepatitis (NASH)
Status:
Planning
Phase of Trial:
Phase II/III
Latest Information Update: 02 Jun 2017
Price :
$35
*
At a glance
- Drugs Remogliflozin etabonate (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Registrational; Therapeutic Use
- Acronyms REIN
- Sponsors Avolynt
- 02 Jun 2017 New trial record